anvisa Setsโข 2026 โขFluโ Vaccine Composition, โขSignals Gradual Phase-Out of Quadrivalent Shots
Brasรญlia, Brazilโข – Brazil’s National Health Surveillanceโฃ Agency โฃ(Anvisa)โ has published Normative Instruction โข408/2025, detailing the required composition of influenza vaccines for the 2026 season in both theโฃ Southern and โขNorthernโค Hemispheres. The directive, released today, specifies the influenza strains thatโ vaccine manufacturers must include inโ their formulations to ensure optimal protection โfor the Brazilian population.
The decision impactsโค all vaccines administered inโข Brazil from February 1, 2026, and comes alongside a โคbroaderโค global trendโ toward phasing out quadrivalent โinfluenza vaccines due to the โฃlackโ of circulating B/Yamagata strain activity.โ Though, Anvisa has persistent โขthat โคanโ immediateโข withdrawal of quadrivalent vaccines in Brazil woudl risk compromising national vaccination coverage, given currentโข market supply.
Southern Hemisphere Vaccines (2026)
Vaccines intended for use inโ the Southern Hemisphere โduring the 2026 season must contain the followingโค strains:
* Trivalent Vaccines: A/Missouri/11/2025 (H1N1)pdm09, A/Singapore/GP20238/2024 (H3N2), and B/Austria/1359417/2021 (Victoria lineage).
* Quadrivalent Vaccines: The above three strains, โคplus B/Phuket/3073/2013 (yamagata lineage).
* Non-Egg-based Vaccines: A/Missouri/11/2025โค (H1N1)pdm09, A/Sydney/1359/2024โข (H3N2), and B/Austria/1359417/2021 โค(Victoria lineage).
All Southern Hemisphere vaccines must be clearly labeled โฃwith “CEPAS 2026 SOUTHERN HEMISPHERE.”
Northern Hemisphere Vaccines (2025-2026)
Vaccines intended for useโ in โMinistry of health campaignsโ targeting specific regions of Brazil during โฃthe 2025-2026 Northern โคHemisphere season must include:
* Trivalent Vaccines: A/Victoria/4897/2022 (H1N1)pdm09,A/Croatia/10136RV/2023โ (H3N2),and B/Austria/1359417/2021 (Victoriaโ lineage).
* โ Quadrivalent Vaccines: The above three strains, plus B/Phuket/3073/2013 (Yamagata lineage).
* Non-egg-Based Vaccines: A/Wisconsin/67/2022 (H1N1)pdm09, A/District of Columbia/27/2023 (H3N2), and B/Phuket/3073/2013 โ(Yamagata lineage).
These vaccines will be labeled with “CEPAS 2025-2026 NORTHERN HEMISFรRIO.”
Quadrivalent โคVaccine Phase-Out
Following โWorld Health association (WHO) recommendations, Anvisa acknowledges the declining prevalence of the B/Yamagata strain, with no confirmed circulation since 2020. โWhile theโค WHO anticipates discontinuing quadrivalent vaccines by 2027, โAnvisa has decided to maintain the supply of these vaccines throughout โค2026 in โBrazil to avoid โขpotential disruptions โtoโค vaccination programs.Theโฃ agency will continue to assess โthe situation andโ adjust its policiesโฃ as needed,balancing global recommendations withโ national โhealthcare needs.